2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2468 Graft-vs-host disease associated with donor-derived clonal hematopoiesis identified by multiomic profiling after hematopoietic cell transplantation for sickle cell disease

Guillem Castro-Bono, MSc, Pandurang Kolekar, PhD2, Mikhail Pogorelyy, PhD3, Arjumand Wani, PhD4, Deanna Langfitt, PhD5, Raghu Shanmugam, PhD6, Jia-Hua Qu, PhD7, Yogesh N.K. Maithania, MS8, Balaji Sundararaman9, Maycon Marção, MS10, Elodie Henriet, PhD11, Aditya Barve, PhD12, Caroline Way, MS13, Laura Jamrog, PhD14, LaShanale Wallace, PhD15, Shannon McKinney-Freeman, PhD16, Faizan Malik, MD17, Julieann C. Lee, MD, MS18, Selene Koo, MD, PhD19, Brandon Triplett, MD20, Heather Sheppard, D.V.M., Ph.D., DACVP21, Jasmine Plummer, PhD22, Stephen Gottschalk, MD23, Xiaotu Ma, PhD24, Paul G Thomas, PhD25, Jeremy Crawford, PhD26, Akshay Sharma Jr, MBBS27, Esther Obeng, MD, PhD28
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
14 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
15 Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States
16 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
18 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
19 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
20 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
21 Arkansas State University, Jonesboro, Arkansas, United States
22 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
23 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
24 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
25 Fred Hutch Cancer Center, Seattle, Washington, United States
26 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
27 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
28 Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States

Introduction

Donor-derived clonal hematopoiesis (CH) is present in 22% of adult allogeneic hematopoietic cell transplant (HCT) recipients. DNMT3A mutations are the most frequent and are associated with an increased risk of graft-vs-host disease (GVHD). Haploidentical donor (HAPLO) HCT expands access to curative therapy for children with sickle cell disease (SCD) lacking a matched sibling donor (MSD). However, increased parental donor age may be associated with donor-derived CH and affect the immune function of the graft. 

 

Patients and Methods

We prospectively followed a cohort of 20 patients that underwent HCT for SCD between 2020 and 2024 on an institutional clinical trial (SCDHCT, NCT04362293). Nine recipients had MSDs and eleven had HAPLO donors. We developed a targeted deep sequencing panel covering 72 CH-associated genes to detect endogenous CH clones and/or the emergence of donor-derived CH clones in bone marrow aspirates obtained pre-HCT, and 1, 3, 12, 24, and 36 months post-HCT. Mutant clone expansion and behavior was further assessed via single cell RNAseq, TIRTLseq (Throughput-Intensive Rapid TCR Library sequencing), spatial transcriptomics and RNA In Situ Hybridization (ISH) analyses of affected tissues.

 

Results

The median age of HAPLO donors (32.4 years) was significantly higher than that of MSDs (17.2 years, p<0.001). Peripheral blood myeloid chimerism was >99% in all recipients. CH clones were not detected in any MSDs, however three (27%) HAPLO donors, ages 33 – 49 years, had DNMT3A-mutant CH. The DNMT3A-mutant clones in two of the HAPLO donors had low variant allele frequencies (VAFs, 0.14% and 0.27%) and were retrospectively identified after DNMT3A-mutant clones emerged in their respective recipients at 36 and 24 months post-HCT. These patients did not develop GVHD. The VAF in the third HAPLO donor was 8.34% and, in the recipient, rapidly expanded to 10.71% at 1 month and 15.6% at 3 months post-HCT. The patient underwent gastrointestinal endoscopic evaluation for GVHD at 2 months post-HCT and presented with intractable seizures at 9 months post-HCT. They were diagnosed with CNS GVHD based on MRI imaging and died from neurologic complications.

We characterized DNMT3A-mutant donor-derived clones in peripheral blood from 3 months post-HCT and endoscopy samples from this patient. Targeted deep sequencing of CD14+ myeloid and CD3+ T cells was notable for 13.7% VAF in myeloid and 4.6% VAF in T cells. Long read single cell RNAseq demonstrated increased inflammatory signatures in peripheral blood DNMT3A-mutant monocytes and CD4+ T cells. Using donor DNMT3A mutation-specific cDNA probes and TIRTLseq, we identified several distinct DNMT3A-mutant peripheral blood T-cell clones and based on the generated data designed custom T cell receptor (TCR) probes for spatial transcriptomic analysis of the endoscopic biopsies. We found an enrichment of DNMT3A-mutant T cells in the colon and duodenum, and neighborhood analysis identified increased associations between DNMT3A-mutant T cells and epithelial and myeloid cells, consistent with the histopathological report of rare crypt apoptosis and focal inflammation. Finally, RNA ISH confirmed DNMT3A-mutant T-cell enrichment in the colon, duodenum, and brain.

 

Conclusions

Our findings highlight that donor-derived DNMT3A-mutant CH is transferred and can expand following HAPLO HCT for SCD. The association of expanding DNMT3A-mutant T-cell clones with GVHD in one patient highlights the potential clinical importance of donor CH screening and warrants further studies of its role in alloHCT-related complications.

Esther Obeng, MD, PhD: No relevant conflicts of interest to declare.